| Literature DB >> 35268417 |
Chester J Koh1,2, Kun Suk Kim3, Jonathan A Gerber1,2, Vinaya Bhatia1,2, Huirong Zhu4, Minki Baek5, Sang Hoon Song1,2,3.
Abstract
We aimed to develop and validate a scoring system as an objective assessment tool for predicting clinical failure after pediatric robotic extravesical ureteral reimplantation. Data for this multi-institutional retrospective cohort was obtained from two tertiary referral hospitals. We defined clinical failure as incomplete radiographic resolution or post-operative febrile UTI. Patients were stratified into low, intermediate, and high-risk groups according to the score. External validation was performed using the model projected to the external validation cohort. An amount of 115 renal units in the development cohort and 46 renal units in the validation cohort were analyzed. The prediction score was calculated with weighted points to each variable according to their regression coefficient as age (year) + BMI + BBD times 10 + VUR grade times 7 + console time (h) + hospital stay times 6. The C-index of our scoring system was 0.850 and 0.770 in the development and validation cohorts, respectively. Clinical failure was significantly different among risk groups: 0% (low-risk), 3.3% (intermediate-risk), and 22.2% (high-risk) (p = 0.004) in the development cohort. A novel scoring system using multiple pre- and intra-operative variables provides a prediction of children at risk of failure after robotic extravesical ureteral reimplantation.Entities:
Keywords: pediatric; robotic surgery; ureteral reimplantation; vesicoureteral reflux
Year: 2022 PMID: 35268417 PMCID: PMC8910908 DOI: 10.3390/jcm11051327
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Patient demographics and pre-operative data.
| Parameters | Development Cohort | Validation Cohort | |
|---|---|---|---|
| No. Patients | 77 | 28 | |
| Total Ureter Units | 115 | 46 | |
| Gender (%) | |||
| Male | 20 (26.0) | 11 (39.3) | 0.122 |
| Female | 57 (74.0) | 17 (60.7) | |
| Median age in years (range) | 5.5 (1–16) | 6.5 (0.3–46) | 0.179 |
| Laterality (%) | |||
| Left | 20 (26.0) | 5 (17.9) | 0.054 |
| Right | 19 (24.7) | 5 (17.9) | |
| Bilateral | 38 (49.4) | 18 (64.3) | |
| BBD | 53 (46.1%) | 5 (10.9%) | <0.001 |
| VUR Grade (%) | |||
| I | 12 (10.4) | 1 (2.2) | 0.048 |
| II | 16 (13.9) | 8 (17.4) | |
| III | 51 (44.3) | 13 (28.3) | |
| IV | 29 (25.2) | 18 (39.1) | |
| V | 7 (6.1) | 6 (13.0) | |
| Median total operative time (min) | 196 (98–273) | 195 (120–360) | 0.927 |
| Median console time (min) | 148 (75–240) | 105 (75–225) | <0.001 |
| Median length of stay in days (range) | 1.0 (1–6) | 2 (2–7) | <0.001 |
| Median follow-up in months (range) | 4.3 (1–19) | 10 (1–41) | <0.001 |
| Follow-up VCUG 1 or RNC 2 conducted (%) | 66 (57.4) | 37 (80.4) | <0.001 |
| Clinical success (%) | 107 (93.0) | 40 (87.0) | 0.227 |
1 Voiding cystourethrography; 2 radionuclide cystogram.
Univariate analysis according to clinical success or failure of renal units in the development cohort.
| Variable | Development Cohort | ||
|---|---|---|---|
| Success ( | Failure ( | ||
| Age | 4.9 (1–16.2) | 8.75 (6–13) | 0.007 |
| Gender | 1.000 | ||
| Female | 81 (75.7%) | 6 (75.0%) | |
| Male | 26 (24.3%) | 2 (25.0%) | |
| BMI 1 | 17.5 (13.4–41.4) | 20.5 (15.2–24.3) | 0.141 |
| BBD 2 | 0.141 | ||
| No | 60 (56.1%) | 2 (25.0%) | |
| Yes | 47 (43.9%) | 6 (75.0%) | |
| Laterality | 0.453 | ||
| Unilateral | 37 (34.6%) | 4 (50.0%) | |
| Bilateral | 70 (94.6%) | 4 (50.0%) | |
| VUR 3 Grade | 0.028 | ||
| I | 12 (11.2%) | 0 (0%) | |
| II | 16 (15.0%) | 0 (0%) | |
| III | 48 (44.9%) | 3 (37.5%) | |
| IV | 27 (25.2%) | 2 (25.0%) | |
| V | 4 (3.7%) | 3 (37.5%) | |
| Console time | 146.0 (75–270) | 188.5 (171–221) | <0.001 |
| No. of detrusorrhaphy stitches | 6 (6–7) | 6 (6–6) | 0.647 |
| Hospital stay | 1 (1–6) | 1.5 (1–3) | 0.595 |
1 BMI, body mass index (kg/m2); 2 BBD, bladder bowel dysfunction; 3 VUR, vesicoureteral reflux.
Multivariate logistic regression models in the development cohort.
| Variable | Without Intra-and Post-Operative Variable Model | With Intra-and Post-Operative Variable Model | ||||||
|---|---|---|---|---|---|---|---|---|
| β Coefficient | OR | 95% CI | β Coefficient | OR | 95% CI | |||
| Age | 0.229 | 1.258 | 0.995–1.591 | 0.056 | 0.43 | 1.54 | 1.03–2.29 | 0.033 |
| BMI 1 | 0.059 | 1.061 | 0.865–1.301 | 0.570 | 0.02 | 1.02 | 0.70–1.51 | 0.883 |
| BBD 2 | 1.512 | 4.538 | 0.699–29.448 | 0.113 | 2.35 | 10.58 | 0.72–182.15 | 0.067 |
| VUR 3 Grade | 1.288 | 3.627 | 1.283–10.252 | 0.015 | 1.96 | 7.12 | 1.19–42.56 | 0.031 |
| Console time | 0.06 | 1.06 | 1.01–1.11 | 0.010 | ||||
| Hospital stay | 1.4 | 4.05 | 0.10–1.33 | 0.130 | ||||
1 BMI, body mass index; 2 BBD, bladder bowel dysfunction; 3 VUR, vesicoureteral reflux.
VUR resolution prediction by risk group.
| Risk Group | Development ( | Validation ( | ||
|---|---|---|---|---|
| Resolution (%) | Resolution | |||
| Low-risk group (<52 points) | 23 (20.0) | 100 | 4 (8.7) | 100 |
| Intermediate-risk group (52–70 points) | 62 (53.9) | 96.8 | 24 (52.2) | 91.7 |
| High-risk group (≥71 points) | 30 (26.1) | 80 | 18 (39.1) | 77.8 |
* Fisher’s exact test (p = 0.007), Fisher’s exact test (p = 0.422).
Figure 1Receiver operating curve analysis of the VUR resolution prediction scoring system for the development cohort (A), area under curve = 0.850, 95% CI = 0.744–0.957, p = 0.001) and the validation cohort (B), area under curve = 0.770, 95% CI = 0.534–1.000, p = 0.040).
Figure 2Receiver operating curve analysis with (A), blue line, area under curve = 0.850, 95% CI = 0.744–0.957, p < 0.001, (B), blue line, area under curve = 0.770, 95% CI = 0.0534–1.000, p = 0.040) or without (A), red line, area under curve = 0.850, 95% CI = 0.737–0.964, p < 0.001, (B), red line, 0.690, 95% CI = 0.448–0.931, p = 0.149) intra- and post-operative variables in the development (A) and validation (B) cohorts.